miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH

The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The inventi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JANICOT, Michel, YAHYANEJAD, Sanaz, VAN PINXTEREN, Laurens Adrianus Hendricus, DE GUNST, Matheus Maria, TELFORD, Bryony, SCHAAPVELD, Roeland Quirinus Jozef, VAN DEN BOSCH, Marion, ALEMDEHY, Mir Farshid
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator JANICOT, Michel
YAHYANEJAD, Sanaz
VAN PINXTEREN, Laurens Adrianus Hendricus
DE GUNST, Matheus Maria
TELFORD, Bryony
SCHAAPVELD, Roeland Quirinus Jozef
VAN DEN BOSCH, Marion
ALEMDEHY, Mir Farshid
description The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment. L'invention concerne l'utilisation de miARN-193a pour réguler l'expression génique, en particulier l'utilisation de miARN-193a en tant qu'agoniste de la CRT, favorisant l'expression de surface cellulaire de la CRT. Cela permet le traitement avantageux de cancers sans ou avec une faible expression de surface de la CRT. L'invention concerne en outre des compositions comprenant le miARN destiné à être utilisé dans un tel traitement.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021170786A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021170786A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021170786A13</originalsourceid><addsrcrecordid>eNrjZNDPzQzyc9Q1tDROVHDzD1IICPL39Q_x9HNX8PT1DfXzd3f183RWcHb18VFwcXUM8eBhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRoaG5gbmFmaOhsbEqQIAph0m8w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH</title><source>esp@cenet</source><creator>JANICOT, Michel ; YAHYANEJAD, Sanaz ; VAN PINXTEREN, Laurens Adrianus Hendricus ; DE GUNST, Matheus Maria ; TELFORD, Bryony ; SCHAAPVELD, Roeland Quirinus Jozef ; VAN DEN BOSCH, Marion ; ALEMDEHY, Mir Farshid</creator><creatorcontrib>JANICOT, Michel ; YAHYANEJAD, Sanaz ; VAN PINXTEREN, Laurens Adrianus Hendricus ; DE GUNST, Matheus Maria ; TELFORD, Bryony ; SCHAAPVELD, Roeland Quirinus Jozef ; VAN DEN BOSCH, Marion ; ALEMDEHY, Mir Farshid</creatorcontrib><description>The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment. L'invention concerne l'utilisation de miARN-193a pour réguler l'expression génique, en particulier l'utilisation de miARN-193a en tant qu'agoniste de la CRT, favorisant l'expression de surface cellulaire de la CRT. Cela permet le traitement avantageux de cancers sans ou avec une faible expression de surface de la CRT. L'invention concerne en outre des compositions comprenant le miARN destiné à être utilisé dans un tel traitement.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210902&amp;DB=EPODOC&amp;CC=WO&amp;NR=2021170786A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20210902&amp;DB=EPODOC&amp;CC=WO&amp;NR=2021170786A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JANICOT, Michel</creatorcontrib><creatorcontrib>YAHYANEJAD, Sanaz</creatorcontrib><creatorcontrib>VAN PINXTEREN, Laurens Adrianus Hendricus</creatorcontrib><creatorcontrib>DE GUNST, Matheus Maria</creatorcontrib><creatorcontrib>TELFORD, Bryony</creatorcontrib><creatorcontrib>SCHAAPVELD, Roeland Quirinus Jozef</creatorcontrib><creatorcontrib>VAN DEN BOSCH, Marion</creatorcontrib><creatorcontrib>ALEMDEHY, Mir Farshid</creatorcontrib><title>miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH</title><description>The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment. L'invention concerne l'utilisation de miARN-193a pour réguler l'expression génique, en particulier l'utilisation de miARN-193a en tant qu'agoniste de la CRT, favorisant l'expression de surface cellulaire de la CRT. Cela permet le traitement avantageux de cancers sans ou avec une faible expression de surface de la CRT. L'invention concerne en outre des compositions comprenant le miARN destiné à être utilisé dans un tel traitement.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDPzQzyc9Q1tDROVHDzD1IICPL39Q_x9HNX8PT1DfXzd3f183RWcHb18VFwcXUM8eBhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGRoaG5gbmFmaOhsbEqQIAph0m8w</recordid><startdate>20210902</startdate><enddate>20210902</enddate><creator>JANICOT, Michel</creator><creator>YAHYANEJAD, Sanaz</creator><creator>VAN PINXTEREN, Laurens Adrianus Hendricus</creator><creator>DE GUNST, Matheus Maria</creator><creator>TELFORD, Bryony</creator><creator>SCHAAPVELD, Roeland Quirinus Jozef</creator><creator>VAN DEN BOSCH, Marion</creator><creator>ALEMDEHY, Mir Farshid</creator><scope>EVB</scope></search><sort><creationdate>20210902</creationdate><title>miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH</title><author>JANICOT, Michel ; YAHYANEJAD, Sanaz ; VAN PINXTEREN, Laurens Adrianus Hendricus ; DE GUNST, Matheus Maria ; TELFORD, Bryony ; SCHAAPVELD, Roeland Quirinus Jozef ; VAN DEN BOSCH, Marion ; ALEMDEHY, Mir Farshid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021170786A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>JANICOT, Michel</creatorcontrib><creatorcontrib>YAHYANEJAD, Sanaz</creatorcontrib><creatorcontrib>VAN PINXTEREN, Laurens Adrianus Hendricus</creatorcontrib><creatorcontrib>DE GUNST, Matheus Maria</creatorcontrib><creatorcontrib>TELFORD, Bryony</creatorcontrib><creatorcontrib>SCHAAPVELD, Roeland Quirinus Jozef</creatorcontrib><creatorcontrib>VAN DEN BOSCH, Marion</creatorcontrib><creatorcontrib>ALEMDEHY, Mir Farshid</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JANICOT, Michel</au><au>YAHYANEJAD, Sanaz</au><au>VAN PINXTEREN, Laurens Adrianus Hendricus</au><au>DE GUNST, Matheus Maria</au><au>TELFORD, Bryony</au><au>SCHAAPVELD, Roeland Quirinus Jozef</au><au>VAN DEN BOSCH, Marion</au><au>ALEMDEHY, Mir Farshid</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH</title><date>2021-09-02</date><risdate>2021</risdate><abstract>The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment. L'invention concerne l'utilisation de miARN-193a pour réguler l'expression génique, en particulier l'utilisation de miARN-193a en tant qu'agoniste de la CRT, favorisant l'expression de surface cellulaire de la CRT. Cela permet le traitement avantageux de cancers sans ou avec une faible expression de surface de la CRT. L'invention concerne en outre des compositions comprenant le miARN destiné à être utilisé dans un tel traitement.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2021170786A1
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
title miRNA-193a FOR PROMOTING IMMUNOGENIC CELL DEATH
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A48%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JANICOT,%20Michel&rft.date=2021-09-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021170786A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true